Adenocarcinomas News and Research

RSS

Review summarises current data on markers for pancreatic cancer

A team of researchers of the UPV/EHU together with researchers from the Hospital Clínico of Barcelona have produced a bibliographical review that summarises the data currently existing on the markers for pancreatic cancer, and have published it in the specialised journal Clinica Chimica Acta.

23 Apr 2013

Researchers identify two specific tumor suppressor genes associated with breast cancer

Research led by Dr. Suresh Alahari, Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans, is the first to report that two specific tumor suppressor genes work in concert to inhibit the growth and spread of breast tumor cells to the lungs.

12 Apr 2013

Researchers develop software tool to noninvasively characterize pulmonary adenocarcinoma

A multidisciplinary team of researchers at Mayo Clinic has developed a new software tool to noninvasively characterize pulmonary adenocarcinoma, a common type of cancerous nodule in the lungs.

9 Apr 2013

Study evaluates efficacy of drug combinations in treating colorectal cancer

Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Once colorectal cancer has spread to other parts of the body, only 11 percent of patients will survive five years from the date of their diagnosis.

8 Apr 2013

Research may offer clues to why esophageal adenocarcinomas rates have increased rapidly

During the past 30 years, the number of patients with cancers that originate near the junction of the esophagus and stomach has increased approximately 600 percent in the United States. The first extensive probe of the DNA of these esophageal adenocarcinomas has revealed that many share a distinctive mix-up of letters of the genetic code, and found more than 20 mutated genes that had not previously been linked to the disease.

25 Mar 2013

Optimal lung cancer screening nodule size questioned

Researchers challenge the definition of a positive result in first-round lung cancer screening with low-dose computed tomography in the Annals of Internal Medicine.

19 Feb 2013

Quarter of incident lung cancer slow growing or indolent

A quarter of incident lung cancers are slow growing or indolent, and may be overdiagnosed, suggest results from sequential low-dose computed tomography screening.

17 Jan 2013

American Thoracic Society, IASLC and ERS propose new sub-classification of lung adenocarcinomas

The International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS), have proposed a new sub-classification of lung adenocarcinomas.

16 Dec 2012

RET fusion signals unique NSCLC subtype

The presence of RET fusion genes in approximately 1.5% of non-small-cell lung cancer defines a subset of tumors with distinct clinicopathologic features, research suggests.

10 Dec 2012

Protective association between statin use and esophageal cancer

Statins, a cholesterol lowering drug may lower the risk of esophageal cancer, especially in patients with Barrett's esophagus, Mayo Clinic researchers report in a study being presented at the American College of Gastroenterology annual meeting.

23 Oct 2012

Aspirin associated with reduced risk of serious ovarian cancer

New research shows that women who regularly use pain relief medications, particularly aspirin, have a decreased risk of serious ovarian cancer—an aggressive carcinoma affecting the surface of the ovary.

10 Oct 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012

Platinum tissue concentrations predict NSCLC treatment response

Reduced tissue platinum accumulation might explain why some patients with non-small-cell lung cancer fail to respond to platinum-based chemotherapy, research shows.

13 Sep 2012

EPHA3 mutations may be important drivers of lung cancers

Vanderbilt-Ingram Cancer Center researchers have identified how one of the genes most commonly mutated in lung cancer may promote such tumors.

31 Jul 2012

Chemotherapy improves survival for patients with periampullary cancer following resection

Patients who had surgery for periampullary cancer (a variety of types of cancer that are located in and near the head of the pancreas, including an area called the ampulla where the bile duct joins up with the pancreatic duct to empty their secretions into the upper small intestine) and received chemotherapy had a statistically significant survival benefit, compared to patients who did not receive chemotherapy, after adjusting for prognostic variables, according to a study in the July 11 issue of JAMA.

11 Jul 2012

CytRx granted European patent for tumor-targeting linker platform technology

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company's tumor-targeting linker platform technology and pharmaceutical compositions.

2 Jul 2012

TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer

An investigational drug that acts like a Trojan Horse to deliver cancer killing agents for pancreatic cancer is being studied at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) that treats cancer patients with promising new drugs.

15 Jun 2012

No benefits to polychemotherapy after surgery in gastric cancer

Findings from the ITACA-S trial suggest that a more intensive postoperative chemotherapy regimen does not improve outcomes over a less-intensive regimen after radical resection in patients with gastric cancer.

7 Jun 2012

CytRx INNO-206 doxorubicin conjugate shows anti-multiple myeloma effects

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the treatment of relapsed multiple myeloma.

30 May 2012

Screening lung cancer tumor samples for genetic mutations can help tailor personalized treatment

Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas — the most common type of non-small cell lung cancer — and have developed drugs that can successfully address them, scientists have not yet identified targeted therapies for another type of non-small cell lung cancer known as squamous cell carcinoma.

19 May 2012